Amgen Prevails In Appeal Of Adverse Inter Partes Review
Mealey's (April 15, 2022, 1:19 PM EDT) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on April 14 reversed findings by the Patent Trial and Appeal Board that 24 claims of an Amgen Inc. recombinant protein...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login